| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.293.109 | 4.095.294 | 3.711.684 | 3.293.427 | 7.353.878 | 6.203.915 | 7.142.597 | 11.299.580 | 12.658.027 | 13.368.623 |
| Total Income - EUR | 3.479.986 | 4.182.601 | 3.861.257 | 3.314.203 | 7.452.948 | 6.257.077 | 7.242.858 | 11.898.973 | 13.549.429 | 13.613.921 |
| Total Expenses - EUR | 2.353.283 | 2.865.342 | 2.760.984 | 2.373.555 | 4.867.577 | 4.312.042 | 5.331.760 | 9.249.752 | 10.051.698 | 10.507.416 |
| Gross Profit/Loss - EUR | 1.126.703 | 1.317.260 | 1.100.273 | 940.648 | 2.585.371 | 1.945.035 | 1.911.098 | 2.649.221 | 3.497.731 | 3.106.505 |
| Net Profit/Loss - EUR | 954.310 | 1.115.340 | 924.668 | 781.313 | 2.165.708 | 1.640.560 | 1.610.952 | 2.238.798 | 2.934.421 | 2.683.878 |
| Employees | 10 | 13 | 12 | 14 | 15 | 15 | 14 | 15 | 15 | 18 |
Check the financial reports for the company - Pharmics Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.740.094 | 1.951.983 | 1.877.551 | 1.733.794 | 1.620.178 | 1.570.680 | 2.118.485 | 2.945.852 | 4.267.212 | 4.556.587 |
| Current Assets | 2.702.282 | 2.747.448 | 2.508.881 | 2.609.122 | 4.180.086 | 4.493.228 | 5.029.551 | 8.279.406 | 9.305.942 | 9.282.956 |
| Inventories | 344.318 | 396.603 | 497.102 | 721.096 | 1.262.395 | 1.184.193 | 1.177.803 | 1.335.772 | 1.139.830 | 1.675.000 |
| Receivables | 763.879 | 601.226 | 660.863 | 792.092 | 1.159.601 | 2.075.771 | 2.840.722 | 4.455.268 | 4.972.474 | 5.899.730 |
| Cash | 1.594.085 | 1.749.618 | 1.350.916 | 1.095.934 | 1.758.091 | 1.233.263 | 1.011.026 | 2.488.366 | 3.193.638 | 1.708.225 |
| Shareholders Funds | 3.158.919 | 3.005.596 | 3.139.720 | 3.359.718 | 4.537.335 | 4.523.951 | 5.105.324 | 3.986.001 | 6.908.335 | 8.090.282 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.291.897 | 1.700.612 | 1.248.542 | 987.887 | 1.267.842 | 1.548.505 | 2.053.292 | 7.247.518 | 6.671.511 | 5.754.874 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Pharmics Srl